warfarine - low molecular heparin — Competitive Intelligence Brief

warfarine - low molecular heparin (warfarine - low molecular heparin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K antagonist. Area: Cardiovascular.

phase 3 Vitamin K antagonist Vitamin K epoxide reductase Cardiovascular Small molecule

Target snapshot

warfarine - low molecular heparin (warfarine - low molecular heparin) — University Hospital, Limoges. Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver, preventing blood clot formation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
warfarine - low molecular heparin TARGET	warfarine - low molecular heparin	University Hospital, Limoges	phase 3	Vitamin K antagonist	Vitamin K epoxide reductase
Indion	PHENINDIONE	Sanofi	marketed	phenindione	Prothrombin, Vitamin K epoxide reductase complex subunit 1, Arachidonate 5-lipoxygenase	1982-01-01
PHYTONADIONE	PHYTONADIONE		marketed	Vitamin K [EPC]	Vitamin K epoxide reductase complex subunit 1 (VKORC1)	1982-01-01
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Standard dose oral anticoagulant	Standard dose oral anticoagulant	Korea University Guro Hospital	marketed	Vitamin K antagonist (warfarin-type oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
standard intensity warfarin	standard intensity warfarin	The First Affiliated Hospital with Nanjing Medical University	marketed	Vitamin K antagonist (VKA)	Vitamin K epoxide reductase complex 1 (VKORC1)
Warfarin or coumadin	Warfarin or coumadin	Ottawa Heart Institute Research Corporation	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K antagonist class)

1. Joon Bum Kim · 1 drug in this class
2. Population Health Research Institute · 1 drug in this class
3. US Department of Veterans Affairs · 1 drug in this class
4. University Hospital, Bonn · 1 drug in this class
5. University Hospital, Limoges · 1 drug in this class
6. Yunhe Pharmaceutical (Tianjin) Co., Ltd · 1 drug in this class